Cargando…

Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database

(1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Qiao, Li, Zhigui, Liu, Yuqing, Luo, Yichen, Fan, Jingya, Xie, Peijun, Cao, Xiaoman, Chen, Xingyu, Wang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857854/
https://www.ncbi.nlm.nih.gov/pubmed/36661721
http://dx.doi.org/10.3390/curroncol30010072
_version_ 1784873952460406784
author Yu, Qiao
Li, Zhigui
Liu, Yuqing
Luo, Yichen
Fan, Jingya
Xie, Peijun
Cao, Xiaoman
Chen, Xingyu
Wang, Xiaodong
author_facet Yu, Qiao
Li, Zhigui
Liu, Yuqing
Luo, Yichen
Fan, Jingya
Xie, Peijun
Cao, Xiaoman
Chen, Xingyu
Wang, Xiaodong
author_sort Yu, Qiao
collection PubMed
description (1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6–9 months and >12 months. The main endpoints were overall survival (OS) and disease-free survival (DFS). (3) Results: Among stage III patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 80.7%% and 66.8%, respectively, and the 5-year OS rates were 94.7%% and 88.8%, respectively. Among high-risk stage II patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 81.5% and 78.6%, respectively, and the 5-year OS rates were 93.1% and 84.2%, respectively. (4) Conclusions: Twelve months of chemotherapy demonstrated superior OS and DFS to that of six months in the stage III group but showed no difference in the high-risk stage II group. The better OS and DFS observed in the 12-month treatment period could be of value in selected cases.
format Online
Article
Text
id pubmed-9857854
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98578542023-01-21 Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database Yu, Qiao Li, Zhigui Liu, Yuqing Luo, Yichen Fan, Jingya Xie, Peijun Cao, Xiaoman Chen, Xingyu Wang, Xiaodong Curr Oncol Article (1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6–9 months and >12 months. The main endpoints were overall survival (OS) and disease-free survival (DFS). (3) Results: Among stage III patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 80.7%% and 66.8%, respectively, and the 5-year OS rates were 94.7%% and 88.8%, respectively. Among high-risk stage II patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 81.5% and 78.6%, respectively, and the 5-year OS rates were 93.1% and 84.2%, respectively. (4) Conclusions: Twelve months of chemotherapy demonstrated superior OS and DFS to that of six months in the stage III group but showed no difference in the high-risk stage II group. The better OS and DFS observed in the 12-month treatment period could be of value in selected cases. MDPI 2023-01-10 /pmc/articles/PMC9857854/ /pubmed/36661721 http://dx.doi.org/10.3390/curroncol30010072 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yu, Qiao
Li, Zhigui
Liu, Yuqing
Luo, Yichen
Fan, Jingya
Xie, Peijun
Cao, Xiaoman
Chen, Xingyu
Wang, Xiaodong
Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
title Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
title_full Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
title_fullStr Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
title_full_unstemmed Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
title_short Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
title_sort effect of different durations of adjuvant capecitabine monotherapy on the outcome of high-risk stage ii and stage iii colorectal cancer: a retrospective study based on a crc database
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857854/
https://www.ncbi.nlm.nih.gov/pubmed/36661721
http://dx.doi.org/10.3390/curroncol30010072
work_keys_str_mv AT yuqiao effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT lizhigui effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT liuyuqing effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT luoyichen effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT fanjingya effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT xiepeijun effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT caoxiaoman effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT chenxingyu effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase
AT wangxiaodong effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase